Kirsten L. Greene, MD

Clinical Instructor, Department of Urology, UCSF

Phone: (415) 353-7171 (appts)
Box 1695, UCSF
San Francisco, CA 94143-1695

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Selected Publications

1. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189(1 Suppl):S2-S11.
   View on PubMed
2. Blaschko SD, Weiss DA, Odisho AY, Greene KL, Cooperberg MR. Proximal bulbar periurethral abscess. Int Braz J Urol. 2013 Jan; 39(1):137-8.
   View on PubMed
3. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94.
   View on PubMed
4. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
   View on PubMed
5. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7.
   View on PubMed
6. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
   View on PubMed
7. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 1; 117(19):4406-13.
   View on PubMed
8. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34.
   View on PubMed
9. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60.
   View on PubMed
10. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182(5):2232-41.
    View on PubMed
11. Breyer BN, Greene KL, Dall'Era MA, Davies BJ, Kane CJ. Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(4):320-4.
    View on PubMed
12. Garcia MM, Gulati S, Liepmann D, Stackhouse GB, Greene K, Stoller ML. Traditional Foley drainage systems--do they drain the bladder? J Urol. 2007 Jan; 177(1):203-7; discussion 207.
    View on PubMed
13. Pookot D, Li LC, Tabatabai ZL, Tanaka Y, Greene KL, Dahiya R. The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol. 2006 Aug; 176(2):793-6.
    View on PubMed
14. Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll PR, Kane CJ. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol. 2006 Jan; 175(1):125-9; discussion 129.
    View on PubMed
15. Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol. 2006; 8(4):190-7.
    View on PubMed
16. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82.
    View on PubMed
17. Meng MV, Greene KL, Turek PJ. Surgery or assisted reproduction? A decision analysis of treatment costs in male infertility. J Urol. 2005 Nov; 174(5):1926-31; discussion 1931.
    View on PubMed
18. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005 Jul 1; 104(1):44-52.
    View on PubMed
19. Greene KL, Meng MV, Abrahams HM, Freise CE, Stoller ML. Laparoscopic-assisted upper pole ureterocalicostomy using renal inversion and autotransplantation. Urology. 2004 Jun; 63(6):1182-4.
    View on PubMed
20. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9.
    View on PubMed

View on UCSF Profiles